Associations - HER-2 mutation

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	afatinib Resistant: A2 - Guideline afatinib Resistant : A2	afatinib Resistant: A2 - Guideline afatinib Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Hormone Receptor Positive Breast Cancer	HER-2 mutation	Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3